利格列汀联合重组人胰岛素治疗2型糖尿病的效果及对脂肪因子的影响  

Effect of Linagliptin Combined with Recombinant Human Insulin in the Treatment of Type 2 Diabetes Mellitus and the Effect on Adipokines

作　　者：李硕[1] 邢林[1] LI Shuo;XING Lin(Department of Endocrinology,Jinan Third People's Hospital,Jinan 250100,Shandong,China)

机构地区：[1]济南市第三人民医院内分泌科,山东济南250100

出　　处：《糖尿病新世界》2025年第1期20-22,26,共4页Diabetes New World

摘　　要：目的探讨2型糖尿病联用利格列汀与重组人胰岛素治疗的效果。方法选取2022年1月—2023年12月济南市第三人民医院收治的80例2型糖尿病患者,根据不同的治疗方法分组。对照组(n=40)使用30/70混合重组人胰岛素注射液治疗,观察组(n=40)使用30/70混合重组人胰岛素注射液联合利格列汀治疗。对两组血糖水平、血脂水平、脂肪因子、不良反应发生情况进行比较。结果治疗后,观察组糖化血红蛋白、空腹血糖、餐后2 h血糖、高密度脂蛋白胆固醇、总胆固醇、甘油三酯、低密度脂蛋白胆固醇、瘦素、脂联素水平均优于对照组,差异均有统计学意义(P均<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论30/70混合重组人胰岛素注射液联合利格列汀治疗可有效治疗2型糖尿病,改善患者的血糖指标、血脂水平和脂肪因子,保证治疗的安全性。Objective To investigate the effect of type 2 diabetes mellitus combined with linagliptin and recombinant human insulin.Methods A total of 80 patients with type 2 diabetes mellitus admitted to Jinan Third People's Hospital from January 2022 to December 2023 were selected.According to different treatment methods,they were grouped.The control group(n=40)was treated with 30/70 mixed recombinant human insulin injection,and the observation group(n=40)was treated with 30/70 mixed recombinant human insulin injection combined with linagliptin.The blood glucose levels,blood lipid levels,adipokines and adverse reactions were compared between the two groups.Results After treatment,the levels of glycated hemoglobin A1c,fasting plasma glucose,2-hour postprandial plasma glucose,high density lipoprotein cholesterol,total cholesterol,triglyceride,low density lipoprotein cholesterol,leptin and adiponectin in the observation group were better than those in the control group,the differences were statistically significant(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The treatment of 30/70 mixed recombinant human insulin injection combined with linagliptin can effectively treat type 2 diabetes mellitus,improve the blood glucose index,blood lipid level and adipokines of patients,and ensure the safety of treatment.

关 键 词：2型糖尿病 30/70混合重组人胰岛素注射液 利格列汀 脂肪因子 不良反应 

分 类 号：R587.1[医药卫生—内分泌]